NCT05898763 2024-11-07
TEIPP
Erasmus Medical Center
Phase 1/2 Completed
Clinical Trials
10 trialsNCT03617328 2024-02-06
Mel-65
University of Virginia
Phase 1/2 Completed
NCT02425306 2023-10-30
Mel63; CHAMP
University of Virginia
Phase 1/2 Terminated
NCT00145158 2022-10-10
Immunization With 8 Peptides Mixed With CpG 7909 or Montanide ISA51 in Patients With Metastatic Cutaneous Melanoma
Ludwig Institute for Cancer Research
Phase 1/2 Terminated
NCT00365937 2019-03-06
Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase 1/2 Terminated
NCT02429440 2017-08-17
UroRCC
University Hospital Tuebingen
Phase 1/2 Unknown
NCT02452307 2017-08-17
Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatectomy
University Hospital Tuebingen
Phase 1/2 Unknown
NCT00089219 2014-11-20
Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma
University of Virginia
Phase 1/2 Completed
NCT00678509 2009-12-29
Histocompatibility Leukocyte Antigen (HLA)-A*2402 Restricted Peptide Vaccine Therapy in Patients With Breast Cancer
Tokyo University
Phase 1/2 Terminated
NCT00683358 2009-05-07
Human Leukocyte Antigen-A*2402-Restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Tokyo University
Phase 1/2 Unknown